A share price of Alnylam Pharmaceuticals Inc [ALNY] is currently trading at $278.76, up 1.17%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ALNY shares have gain 11.88% over the last week, with a monthly amount glided 13.58%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] stock has seen the most recent analyst activity on November 12, 2024, when Wolfe Research downgraded its rating to a Underperform. On August 16, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $370 on the stock. Goldman downgraded its rating to a Neutral but stick to its price target of $173 on February 16, 2024. Wolfe Research initiated its recommendation with a Peer Perform. Wells Fargo started tracking with a Equal Weight rating for this stock on December 08, 2023, and assigned it a price target of $171. In a note dated December 08, 2023, Wells Fargo initiated an Equal Weight rating.
Alnylam Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $141.98 and $304.39. Currently, Wall Street analysts expect the stock to reach $320.5 within the next 12 months. Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] shares were valued at $278.76 at the most recent close of the market. An investor can expect a potential return of 14.97% based on the average ALNY price forecast.
Analyzing the ALNY fundamentals
Trailing Twelve Months sales for Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] were 2.09B which represents -33.26% decline. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -0.09%, Pretax Profit Margin comes in at -0.15%, and Net Profit Margin reading is -0.16%. To continue investigating profitability, this company’s Return on Assets is posted at -0.08, Equity is 3.24 and Total Capital is -0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 40.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 273.63 points at the first support level, and at 268.50 for the second support level. However, for the 1st resistance point, the stock is sitting at 281.78, and for the 2nd resistance point, it is at 284.80.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] is 2.75. Further, the Quick Ratio stands at 2.69, while the Cash Ratio is 0.9. Considering the valuation of this stock, the price to sales ratio is 17.16, the price to book ratio is 1110.07.
Transactions by insiders
Recent insider trading involved SHARP PHILLIP A, Director, that happened on Jan 23 ’25 when 11250.0 shares were sold. Director, SHARP PHILLIP A completed a deal on Jan 23 ’25 to buy 11250.0 shares. Meanwhile, CMO & EVP Dev & Med Affairs Garg Pushkal sold 1752.0 shares on Dec 12 ’24.
